Fervent Synergies Limited
BSE: FERVENTSYN · Trading & Distributors
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Fervent Synergies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fervent Synergies Limited is a diversified Indian entity operating primarily in the pharmaceutical trading and financial services sectors. The company focuses on the wholesale distribution of pharmaceutical raw materials and active ingredients, alongside providing corporate loans and investment services.
Business Model
The company generates revenue through the wholesale trading of chemical and pharmaceutical inputs and by earning interest and returns from its financial lending and investment portfolio.
Growth Outlook
Growth is driven by identifying strategic opportunities within the healthcare supply chain and expanding its footprint in capital markets through corporate financing activities.
Key Risks
- Market Volatility. The company's investment portfolio is susceptible to fluctuations in capital markets and interest rate changes.
- Supply Chain Dependency. As a trader of pharmaceutical raw materials, the firm faces risks related to global supply chain disruptions and price volatility of chemical inputs.
- Credit Risk. The provision of loans and advances exposes the company to potential defaults by borrowers within its financial services segment.
- Regulatory Compliance. Operating in the pharmaceutical sector requires strict adherence to evolving domestic regulations and quality standards.
Start your research today
Unlock AI insights, financials, peers and live data on Fervent Synergies Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹16 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹0.77
TTM · standalone
RETURN ON EQUITY
7.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
7.5%
TTM · standalone
P/E
19.0x
Q4 FY26 · standalone
EV/EBITDA
19.7x
Q4 FY26 · standalone
EBITDA MARGIN
23.9%
TTM · standalone
NET PROFIT MARGIN
16.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Trading & Distributors
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Fervent Synergies LimitedFERVENTSYN | ₹77 Cr | 19.04 | 19.74 | -49.7% | 23.9% | 7.5% | 7.5% | -36.2% |
Veritas (India)VERITAS | ₹417 Cr | -493.83 | 11.83 | -12.9% | 2.0% | 0.0% | 0.9% | -56.4% |
Kothari ProductsKOTHARIPRO | ₹416 Cr | 167.82 | -12.33 | -18.3% | -5.1% | -0.2% | -2.3% | -30.8% |
Rotographics (India) LimitedRGIL | ₹330 Cr | 52.46 | 198.17 | 301.6% | 3.7% | 11.6% | 15.9% | -60.7% |
Polo Queen Industrial and Fintech LimitedPQIF | ₹270 Cr | 130.17 | 56.64 | -2.0% | 7.0% | 1.2% | 2.3% | -81.3% |
Constronics Infra Ltd.CONSTRONIC | ₹63 Cr | 23.27 | 22.03 | — | 8.0% | 6.0% | 6.0% | -26.4% |
As of Q4 FY26
Financials
Fervent Synergies Limited
BSE: FERVENTSYN · Trading & Distributors
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock Fervent Synergies Limited's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Fervent Synergies Limited is a diversified Indian entity operating primarily in the pharmaceutical trading and financial services sectors. The company focuses on the wholesale distribution of pharmaceutical raw materials and active ingredients, alongside providing corporate loans and investment services.
Business Model
The company generates revenue through the wholesale trading of chemical and pharmaceutical inputs and by earning interest and returns from its financial lending and investment portfolio.
Growth Outlook
Growth is driven by identifying strategic opportunities within the healthcare supply chain and expanding its footprint in capital markets through corporate financing activities.
Key Risks
- Market Volatility. The company's investment portfolio is susceptible to fluctuations in capital markets and interest rate changes.
- Supply Chain Dependency. As a trader of pharmaceutical raw materials, the firm faces risks related to global supply chain disruptions and price volatility of chemical inputs.
- Credit Risk. The provision of loans and advances exposes the company to potential defaults by borrowers within its financial services segment.
- Regulatory Compliance. Operating in the pharmaceutical sector requires strict adherence to evolving domestic regulations and quality standards.
Start your research today
Unlock AI insights, financials, peers and live data on Fervent Synergies Limited and 5,000+ companies — free.
Key Metrics
REVENUE
₹16 Cr
TTM · standalone
NET PROFIT
₹4 Cr
TTM · standalone
EPS
₹0.77
TTM · standalone
RETURN ON EQUITY
7.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
7.5%
TTM · standalone
P/E
19.0x
Q4 FY26 · standalone
EV/EBITDA
19.7x
Q4 FY26 · standalone
EBITDA MARGIN
23.9%
TTM · standalone
NET PROFIT MARGIN
16.7%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Trading & Distributors
As of Q4 FY26